Purpose: Intracavernosal injections are used to treat erectile dysfunction. Patient compliance with intracavernosal injections is required for success, though factors influencing compliance are unknown. This study aimed to identify factors that influence compliance with intracavernosal injections among men with erectile dysfunction.
Materials And Methods: A retrospective analysis was conducted using men who were prescribed intracavernosal injections between 2017 and 2022 at an academic medical center in a cosmopolitan area. Custom Python code was used to capture the first and last prescription refill events, and the duration of intracavernosal injection use was calculated. Additional patientrelated data, including demographics and comorbidities, were gathered through chart reviews. Cox Proportional Hazards Regression models were used to evaluate the effects of predictor variables on the duration of intracavernosal injection use.
Results: A total of 4,072 patients were included in the analysis. The study revealed that age significantly predicted discontinuation of intracavernosal injection therapy, showing an elevated hazard ratio of 1.007 for each additional year of age (p<0.001). Men who preferred to speak Spanish as their primary language was a significant predictor of discontinuation of injection therapy, showing a hazard ratio of 1.163 compared to those who preferred English (p=0.004). Men with a history of prostate cancer treatment stayed on treatment for 80 days fewer on average than those without (p=0.002).
Conclusions: Older age, prior history of prostate cancer treatment, and men who preferred to speak Spanish were all identified as factors potentially associated with reduced continuation of intracavernosal injection therapy for erectile dysfunction. Understanding these factors can help healthcare providers in both patient selection and counseling when discussing treatment options for erectile dysfunction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5534/wjmh.230329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic management of erectile dysfunction: the AFU/SFMS guidelines.
Fr J Urol
December 2024
Department of Urology, Hospital of Monaco, France.
Context: Erectile dysfunction (ED) is a common sexual disorder. In France, recent evidence-based guidelines are lacking.
Aim: To provide practice guidelines on ED therapeutic management.
The feasibility study of shear wave elastography in the diagnosis of erectile dysfunction.
Sci Rep
November 2024
Department of Ultrasound, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No.1, Xiyuan Playground, Haidian District, Beijing, 100091, China.
The aim of this study was to explore the value of Shear wave elastography (SWE) in evaluating vascular and nonvascular erectile dysfunction. In this study, erectile dysfunction (ED) patients enrolled (n = 114) received SWE and Doppler ultrasonography (PCDU) exams. The peak systolic velocity (PSV) and end-diastolic velocity (EDV) were used as the classification standard.
View Article and Find Full Text PDFDiscrepancy Between Patient vs Provider Assessment of Erection Quality.
Urology
October 2024
Department of Urology, Mayo Clinic Health System, Mankato, MN.
Objective: To characterize the discrepancy between patients' and providers' assessments of erection rigidity and its association with patient characteristics and penile ultrasound parameters.
Methods: Patients presenting for penile Doppler ultrasound between July 2022 and October 2023 were reviewed retrospectively. After intracavernosal injection, patients and providers independently rated erection rigidity from 1 to 10 prior to ultrasound.
Pain associated with prostaglandin E-containing intracavernosal injection medication is associated with poor erectile function recovery after radical prostatectomy.
Andrology
October 2024
Sexual and Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Background: Intracavernosal injection therapy is often used as second-line therapy for erectile dysfunction associated with radical prostatectomy when therapy with phosphodiesterase-5 inhibitors has failed, but prostaglandin E1-containing vasoactive agents are associated with penile pain in some men.
Objectives: To define the incidence of pain with prostaglandin E1-containing intracavernosal injection mixtures for erectile dysfunction associated with radical prostatectomy when therapy with phosphodiesterase-5 inhibitors has failed, and whether pain was a predictor of erectile function recovery.
Materials And Methods: Men who underwent radical prostatectomy and were commenced on intracavernosal injection within 12 months of radical prostatectomy were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!